Market revenue in 2023 | USD 94.9 million |
Market revenue in 2030 | USD 141.8 million |
Growth rate | 5.9% (CAGR from 2023 to 2030) |
Largest segment | Stimulants |
Fastest growing segment | Non-stimulants |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Stimulants, Non-stimulants |
Key market players worldwide | Eli Lilly and Co, Pfizer Inc, Johnson & Johnson, Lupin, Novartis AG ADR, Takeda Pharmaceutical Co Ltd, Mallinckrodt PLC Ordinary Shares - New, Vital KSK Holdings Inc, NeuroSense Therapeutics Ltd, Supernus Pharmaceuticals Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to attention deficit hyperactivity disorder market will help companies and investors design strategic landscapes.
Stimulants was the largest segment with a revenue share of 70.92% in 2023. Horizon Databook has segmented the South Korea attention deficit hyperactivity disorder market based on stimulants, non-stimulants covering the revenue growth of each sub-segment from 2018 to 2030.
ADHD medications are proven to be effective in improving symptoms associated with ADHD. Due to the chronic nature of ADHD, patients with ADHD require long-term pharmacotherapy. Currently, the two major evidence-based treatments are pharmacotherapy and behavioral therapy.
Pharmacotherapy with stimulants, such as amphetamines and methylphenidate, is used as a first-line treatment option for ADHD patients. Other treatments with nonstimulants, such as clonidine hydrochloride, guanfacine extended-release, and atomoxetine, are also used to treat ADHD patients.
In addition, extended-released methylphenidate, immediate-release methylphenidate, osmoticcontrolled release oral delivery system methylphenidate, and atomoxetine are the medications approved for reimbursement by the Health Insurance Review and Assessment Service (HIRA) in South Korea.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea attention deficit hyperactivity disorder market , including forecasts for subscribers. This country databook contains high-level insights into South Korea attention deficit hyperactivity disorder market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account